3 de febrero de 2016 / 13:04 / en 2 años

BRIEF-GSK CEO says consumer spin-off very unlikely in short term

Feb 3 (Reuters) - GlaxoSmithKline CEO Andrew Witty told reporters:

* willing to have some vaccine capability on standby for coping with crises like Zika

* reiterates now has consumer business that could stand alone

* “unwise” to make definitive choice on consumer spin-off in short term

* chances of doing something on consumer unit in accelerated time frame very unlikely

* importance of Advair to GSK has shifted enormously in last 24-36 months

* UK better off inside EU from business perspective

* as of today would not recommend changing status quo of consumer business

* U.S. market has got a lot harder Further company coverage: (Reporting by UK bureau)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below